['metastatic castration-resistant prostate cancer']
['taxotere', 'jevtana']

        Inclusion Criteria:

          -  Affiliated to a social security regimen ;

          -  Male patients older than 18 years ;

          -  Histologically confirmed adenocarcinoma of the prostate ;

          -  Continued androgen deprivation therapy either by LHRH agonists/antagonists or
             orchidectomy ;

          -  Serum testosterone <0.50 ng/ml (1.7 nmol/L) ;

          -  Progressive disease (PSA progression or radiological progression or clinical
             progression) ;

          -  ECOG 0-2 ;

          -  Information delivered to patient and informed consent form signed by the patient or
             his legal representative ;

          -  Adequate organ or bone marrow function as evidenced by:

               -  Hemoglobin >/= 10 g/dL

               -  Absolute neutrophil count >/=1.5 x 109/L,

               -  Platelet count >/=100 x 109/L,

               -  AST/SGOT and/or ALT/SGPT </=1.5 x ULN;

               -  Total bilirubin </=1.5 x ULN,

               -  Serum creatinine </=1.5 x ULN. If creatinine 1.0 - 1.5 xULN, creatinine clearance
                  will be calculated according to CKD-EPI formula and patients with creatinine
                  clearance <60 mL/min should be excluded

        Exclusion Criteria:

          -  Patients having received an investigational drug and/or prior surgery, radiation,
             chemotherapy, or other anti-cancer therapy within 4 weeks prior enrolment in the
             study, excepted radiotherapy directed to a single bone lesions which is nonacceptable
             if within 2 weeks ;

          -  Prior treatment with Taxotere or Jevtana ;

          -  Pre-existing symptomatic peripheral neuropathy grade > 2 (CTCAE V4) ;

          -  Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of
             congestive heart failure (NYHA III or IV) or myocardial infarction within last 6
             months is also not allowed ;

          -  History of severe hypersensitivity reaction (grade ≥3) to polysorbate 80 containing
             drugs ;

          -  Uncontrolled severe illness or medical condition (including uncontrolled diabetes
             mellitus), active infection including HIV infection, active Hepatitis B or C infection
             that would preclude participation in the trial ;

          -  Concurrent or planned treatment with strong inhibitors or strong inducers of
             cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are
             already on these treatments) ;
      